Conatus pharmaceuticals inc. (CNAT)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenues:
Collaboration revenue

21,717

33,586

35,377

799

-

-

-

-

-

Collaboration revenue

-

-

-

-

0

-

-

-

-

Total revenues

21,717

33,586

35,377

799

0

-

-

-

-

Operating expenses:
Research and development

23,527

41,368

43,220

20,294

16,297

14,908

6,947

5,528

9,486

General and administrative

10,196

10,495

9,707

10,337

7,833

7,379

4,650

3,086

2,874

Total operating expenses

33,723

51,863

52,927

30,631

24,130

22,288

11,598

8,614

12,361

Loss from operations

-12,006

-18,277

-17,550

-29,832

-24,130

-22,288

-

-

-

Other income (expense):
Interest income

568

962

892

138

-

-

-

-

-

Interest income

-

-

-

-

67

57

22

25

28

Interest expense

0

696

662

70

70

70

462

70

113

Other income (expense)

53

1

-76

30

-15

-19

-1

1

-4

Other financing expense

-

-

-

-

-

-

-3,576

-91

454

Total other income

621

267

154

98

-17

-31

-4,018

-134

364

Net loss

-11,385

-18,010

-17,396

-29,734

-24,148

-22,319

-15,616

-8,749

-11,996

Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities

17

60

-71

-2

9

-24

10

5

-4

Comprehensive loss

-11,368

-17,950

-17,467

-29,736

-24,139

-22,344

-15,605

-8,744

-12,001

Net loss

-11,385

-18,010

-17,396

-29,734

-24,148

-

-15,616

-8,749

-11,996

Gain on extinguishment of convertible preferred stock

-

-

-

-

-

-

11,491

-

-

Deemed distribution from promissory note issuance

-

-

-

-

-

-

474

-

-

Net loss applicable to common stockholders

-

-

-

-

-

-

-4,600

-8,749

-11,996

Net loss per share, basic and diluted

-0.34

-0.59

-0.61

-1.31

-1.30

-1.44

-0.63

-8.60

-11.86

Weighted average shares outstanding used in computing net loss per share, basic and diluted

33,169

30,370

28,587

22,650

18,617

15,478

7,358

1,016

1,011